Cervical Cancer Clinical Trial
Official title:
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
This primary goal of this study is to assess whether patient whose parents watch a
standardized digital video using the integrated digital approach during a routine office
visit are more likely to accept a dose of HPV vaccine (1st, 2nd, or 3rd dose) compared to
those not completing the program. The study team anticipates eligible patients in the
intervention clinics to have higher rates of HPV vaccine acceptance (1st, 2nd, or 3rd doses)
than patients in the usual care comparison clinics.
Additionally, the study team is interested in determining the impact of the integrated
system on clinical workflow by measuring the number of minutes of each patient office visit
when using the system compared to the number of minutes of each visit in offices where the
system is not used.
Although this is a descriptive/exploratory aim, our expectation is that the THEO system will
have minimal impact on patient flow.
Brief Summary of Design: This is a 2-arm randomized study, with randomization occurring at
the level of clinic. Five clinics will be included (2 implementing the THEO video; 3
providing usual care). All five clinics have been using the Child Health Improvement through
Computer Automation System (CHICA) for several years. The evaluation phase of the study will
last for approximately 6-7 months.
The CHICA System
The Child Health Improvement through Computer Automation system (CHICA) is a computer based
decision support system that operates as a front end to the electronic medical record system
(EMR). When a child is registered in the clinic, the registration system sends an HL7 ADT
(registration) message to CHICA. In response, CHICA requests a download of the patient's
record from the EMR. CHICA applies a rule base consisting of hundreds of Arden Syntax rules
to the data in the record to select 20 yes/no questions that are displayed on an electronic
tablet. The family answers the questions and returns the tablet to the medical assistant who
enters the child's height, weight and other measurements onto another page on the tablet.
At the same time that CHICA produces the questions for family, it sends an HL7 request to
CHIRP, the Indiana immunization registry. In response, CHICA receives a download of the
child's immunization record. The download includes CHIRP's "forecast" of the immunizations
for which the patient is due.
At the end of these processes, CHICA produces several paper documents. The first is the
physician worksheet (PWS). The PWS includes up to six alerts and reminders for the
physician. The reminders are selected by CHICA, using its Arden Syntax rule set based on the
patient's EMR and answers provided on the tablet. Each alert has up to six check boxes with
which the physician can document how s/he responded to the alert. The PWS, when completed,
is scanned, the coded data corresponding to the check boxes are stored, and text is written
into the physician's note in the medical record. CHICA may also produce any of a large
number of handouts for helping the physician with assessment or patient education. CHICA
also produces a summary of the patient's immunization history as well and advice on what
shots the child is due to receive.
In an ongoing study of the Regenstrief-Merck collaboration, the investigators are studying
the effect of providing physicians with a suggested "script" for recommending HPV
vaccination to eligible patients' families. The study randomizes by physician whether the
script is provided or whether the physician receives a simple reminder.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |